Celyad Oncology SA CLYYF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -703.70K | -707.90K | 2.62M | 2.63M | -2.09M |
| Total Depreciation and Amortization | 25.00K | 25.20K | -53.00K | -53.20K | 115.80K |
| Total Amortization of Deferred Charges | -- | -- | 34.30K | 34.50K | -- |
| Total Other Non-Cash Items | -59.90K | -60.30K | -3.84M | -3.86M | 97.00K |
| Change in Net Operating Assets | -122.70K | -123.40K | -871.90K | -875.70K | 14.80K |
| Cash from Operations | -861.30K | -866.40K | -2.11M | -2.12M | -1.86M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | 1.75M | 1.76M | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | 1.75M | 1.76M | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -26.50K | -26.50K | -36.50K |
| Issuance of Common Stock | -- | -- | 482.50K | 482.50K | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -54.00K | -54.00K | 309.00K | 309.00K | -31.50K |
| Cash from Financing | -62.80K | -63.20K | 890.50K | 894.40K | -77.20K |
| Foreign Exchange rate Adjustments | 1.20K | 1.20K | 3.50K | 3.50K | 600.00 |
| Miscellaneous Cash Flow Adjustments | -- | -- | 600.00 | 600.00 | -600.00 |
| Net Change in Cash | -922.90K | -928.40K | 534.30K | 536.60K | -1.94M |